P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 12, 2001, Pages 3437-3444

  Sajjan, U S ^a   Tran, L T ^a   Sole, N ^a   Rovaldi, C ^a   Akiyama, A ^a   Friden, P M ^a   Forstner, J F ^a   Rothstein, D M ^a  

^a Demegen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEFTAZIDIME; GENTAMICIN; PIPERACILLIN; POLYPEPTIDE ANTIBIOTIC AGENT; SARALASIN; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; ENZYME ACTIVITY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SALIVARY GLAND; SPUTUM ANALYSIS;

ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DEOXYRIBONUCLEASES; HUMANS; ISOMERISM; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SARALASIN; SPUTUM; STEREOISOMERISM;

EID: 0035185146     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.12.3437-3444.2001     Document Type: Article

References (44)

1. Dynamic interactions of biofilms of mucoid Pseudomonas aeruginosa with tobramycin and piperacillin
2. All-D-magainin: Chirality, antimicrobial activity and proteolytic resistance
3. Mass spectrometry of peptides and proteins
4. Microbiology of sputum from patients at cystic fibrosis centers in the United States
5. Cystic fibrosis
6. Antimicrobial treatment of pulmonary colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients
7. Improved survival in the Danish center-treated cystic fibrosis patients: Results of aggressive treatment
8. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in vivo selection of stable partially derepressed β-lactamase-producing strains
9. Microbial pathogenesis in cystic fibrosis mucoid Pseudomonas aeruginosa and Burkholderia cepacia
10. Peptide antibiotics
11. Peptide antibiotics
12. The role of antimicrobial peptides in animal defenses
13. Genetic and immunological aspects of cystic fibrosis
14. Macromolecular mechanisms of sputum inhibition of tobramycin activity
15. Production of elastase, exotoxin A, and alkaline protease in sputa during pulmonary exacerbation of cystic fibrosis in patients chronically infected by Pseudomonas aerginosa
16. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
17. Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology
18. Effect of high-dose ibuprofen in patients with cystic fibrosis
19. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: Comparison with activity in serum
20. Growth-inhibitory and bactericidal effects of human parotid salivary histidine-rich polypeptides on Streptococcus mutans
21. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis
22. Rapid characterization of periodontal bacterial isolates by using fluorogenic substrate tests
23. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum
24. Clinical and microbial evaluation of a histatin containing mouthrinse in humans with experimental gingivitis
25. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis
26. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection
27. Histatins, a novel family of histidinerich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans
28. Inhibition of experimental gingivitis in beagle dogs with topical salivary histatins
29. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis
30. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections
31. Salivary histatin 5: Dependence of sequence, chain length, and helical conformation for candidacidal activity
32. Membrane-induced helical conformation of an active candidacidal fragment of salivary histatins
33. The binding of antipseudomonal antibiotics to macromolecules from cystic fibrosis sputum
34. Management of pulmonary disease in patients with cystic fibrosis
35. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
36. Cystic fibrosis
37. Anticandidal activity is retained in P-113, a 12-amino-acid fragment of histatin 5
38. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation
39. Pathogenesis of bacterial bronchitis in cystic fibrosis
40. Anti-lipopolysaccharide activity of histatins, peptides from human saliva
41. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection
42. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
43. Membrane proteins: From sequence to structure
44. Research on cystic fibrosis: A journey from the heart house